Please Enable Cookies

www.cablinginstall.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longboard Pharmaceuticals Inc (NQ: LBPH )

35.50 +1.90 (+5.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 640,799
Open 33.80
Bid (Size) 35.08 (1)
Ask (Size) 37.00 (13)
Prev. Close 33.60
Today's Range 33.56 - 36.38
52wk Range 3.600 - 40.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
These three small-cap stocks could deliver hefty returns if the central bank cuts rates. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+41.43%
+41.43%
1 Month
+70.51%
+70.51%
3 Month
+79.75%
+79.75%
6 Month
+38.29%
+38.29%
1 Year
+419.01%
+419.01%

More News

Read More
Top 3 Health Care Stocks That May Crash This Quarter
Via Benzinga
Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Recap: Longboard Pharmaceuticals Q4 Earnings
Via Benzinga
Looking Into Longboard Pharmaceuticals's Recent Short Interest
Via Benzinga
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
LBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher
Via The Motley Fool
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Longboard Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Longboard Pharmaceuticals, Inc.
Via Business Wire
This biotech stock has surged over 300% this week
Via MarketBeat
Jim Cramer: This Energy Firm Has 'Good Growth, Good Yield' But As For IonQ? Ixnay
Via Benzinga
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Why Longboard Pharmaceuticals Stock Is Falling
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.